We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Test for Ovarian Cancer Helps Determine Type of Required Surgery

By LabMedica International staff writers
Posted on 17 Sep 2009
Ovarian cancer can be detected in a pelvic mass that is already known to require surgery, helping patients and health care professionals decide what type of surgery should be done and by whom.

Called OVA1, the qualitative serum test for ovarian cancer combines the results of five immunoassays into a single numerical score. More...
The test is indicated for women who meet the following criteria: the patient is over age 18, an ovarian adnexal mass is present for which surgery is planned, and the patient has not yet been referred to an oncologist.

The immunoassay identifies five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II). An algorithm is then used to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

OVA1test was developed by Vermillion, Inc. (Freemont, CA, USA) a molecular diagnostics company, in cooperation with Quest Diagnostics (Madison, NJ, USA), a provider of cancer diagnostics. Quest Diagnostics has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years. The U.S. Food and Drug Administration (FDA) has cleared the OVA1 test, as an indication of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even when radiological test results fail to indicate malignancy.

The test should not be used without an independent clinical/radiological evaluation. It is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Vermillion, Inc. is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. Vermillion has diagnostic programs in oncology, hematology, cardiology, and women's health.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.

Related Links:
Vermillion, Inc.
Quest Diagnostics


New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Collection and Transport System
PurSafe Plus®
Laboratory Software
ArtelWare
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.